The Mechanism and Utility of CPI-613 for the Treatment of Hematologic Malignancies

In an interview with Targeted Oncology for World Cancer Day, Manmeet Ahluwalia, MD, MBA, FASCO, explored the key challenges facing community oncology and the strategies needed to close these gaps.

Marwan G. Fakih, MD, discussed the implications of the findings from the phase 2 study for patients with microsatellite stable metastatic colorectal cancer without liver metastases.

Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies are offering hope for more durable remissions and better quality of life.

Daniel Rubin, PharmD, BCOP, discussed a study showing how a clinical decision support tool can improve the documentation of biomarker results in cancer care.

The combination of treosulfan and fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia or myelodysplastic syndromes has been approved by the FDA.

The CELESTIAL-301 trial evaluating SynKIR-310, a novel CAR T-cell therapy, has dosed its first patient with relapsed/refractory B-cell non-Hodgkin lymphoma.